生物可降解聚合物西罗莫司洗脱支架与耐久聚合物依维莫司洗脱支架在ST段抬高型心肌梗死患者中的比较(BIOSTEMI):单盲、前瞻性、随机优效性试验
BIOSTEMI试验为研究者发起的多中心、前瞻性、单盲、随机优效性试验,在瑞士10家医院纳入1300例(1623处病变)因急性STEMI接受直接PCI的患者,随机1:1分配至生物可降解聚合物西罗莫司洗脱支架组(649例)或耐久聚合物依维莫司洗脱支架组(651例)。主要终点为12个月内靶病变失败(心源性死亡、靶血管心肌再梗死、临床指示的靶病变血运重建的复合终点)。结果显示,生物可降解聚合物西罗莫司洗脱支架组25例(4%)发生主要终点,耐久聚合物依维莫司洗脱支架组36例(6%)(差值-1.6个百分点;率比0.59,95%贝叶斯可信区间0.37-0.94;优效性后验概率0.986)。两组心源性死亡、靶血管心肌再梗死、临床指示的靶病变血运重建及明确支架血栓在12个月随访中相似。作者认为,在急性STEMI直接PCI患者中,生物可降解聚合物西罗莫司洗脱支架在1年靶病变失败方面优于耐久聚合物依维莫司洗脱支架,差异由生物可降解聚合物西罗莫司洗脱支架组缺血驱动的靶病变血运重建减少所驱动。
要点
- 在急性STEMI直接PCI患者中,生物可降解聚合物西罗莫司洗脱支架组1年靶病变失败发生率为4%(25/649),耐久聚合物依维莫司洗脱支架组为6%(36/651),率比0.59(95%贝叶斯可信区间0.37-0.94)。
- 两组心源性死亡、靶血管心肌再梗死、临床指示的靶病变血运重建及明确支架血栓在12个月随访中相似。
- 主要终点差异由生物可降解聚合物西罗莫司洗脱支架组缺血驱动的靶病变血运重建减少所驱动。
- 该试验为单盲设计,患者和治疗医生知晓分组,结局评估者设盲。
- 研究在瑞士10家医院进行,纳入18岁及以上因急性STEMI转诊行直接PCI的患者。
适用人群与场景
- 年龄18岁及以上、因急性ST段抬高型心肌梗死(STEMI)转诊行直接经皮冠状动脉介入治疗(PCI)的患者。
- 研究在瑞士10家医院进行,纳入时间为2016年4月26日至2018年3月9日。
处置流程与药物剂量
- 患者随机1:1分配至生物可降解聚合物西罗莫司洗脱支架(Orsiro;Biotronik;Bülach,瑞士)或耐久聚合物依维莫司洗脱支架(Xience Xpedition/Alpine;Abbott Vascular,Abbott Park,IL,美国)。
- 生物可降解聚合物西罗莫司洗脱支架为超薄 strut 钴铬金属支架平台,从生物可降解聚合物释放西罗莫司。
- 耐久聚合物依维莫司洗脱支架为薄 strut 钴铬支架平台,从耐久聚合物释放依维莫司。
研究设计与关键结果
- BIOSTEMI为研究者发起的多中心、前瞻性、单盲、随机优效性试验,在瑞士10家医院纳入1300例患者(1623处病变),随机分配至生物可降解聚合物西罗莫司洗脱支架组(649例患者,816处病变)或耐久聚合物依维莫司洗脱支架组(651例患者,806处病变)。
- 12个月随访数据:生物可降解聚合物西罗莫司洗脱支架组614例(95%)患者、耐久聚合物依维莫司洗脱支架组626例(96%)患者可获取。
- 主要复合终点靶病变失败(心源性死亡、靶血管心肌再梗死(Q波和非Q波)、临床指示的靶病变血运重建)在生物可降解聚合物西罗莫司洗脱支架组发生25例(4%),耐久聚合物依维莫司洗脱支架组发生36例(6%)(差值-1.6个百分点;率比0.59,95%贝叶斯可信区间0.37-0.94;优效性后验概率0.986)。
- 心源性死亡、靶血管心肌再梗死、临床指示的靶病变血运重建及明确支架血栓在两组12个月随访中相似。
- 作者认为,差异由生物可降解聚合物西罗莫司洗脱支架组缺血驱动的靶病变血运重建减少所驱动。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、单盲、随机优效性试验。
- 试验注册号:ClinicalTrials.gov,NCT02579031。
- 资助:Biotronik。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在因急性STEMI接受直接PCI的患者中,选择生物可降解聚合物西罗莫司洗脱支架相比耐久聚合物依维莫司洗脱支架可降低1年靶病变失败风险(4% vs 6%),主要由缺血驱动的靶病变血运重建减少所驱动。
- 两组心源性死亡、靶血管心肌再梗死、临床指示的靶病变血运重建及明确支架血栓在12个月随访中相似。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Newer-generation drug-eluting stents that combine ultrathin strut metallic platforms with biodegradable polymers might facilitate vascular healing and improve clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI) compared with contemporary thin strut second-generation drug-eluting stents. We did a randomised clinical trial to investigate the safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stents versus thin strut durable polymer everolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
METHODS: The BIOSTEMI trial was an investigator-initiated, multicentre, prospective, single-blind, randomised superiority trial at ten hospitals in Switzerland. Patients aged 18 years or older with acute STEMI who were referred for primary PCI were eligible to participate. Patients were randomly allocated (1:1) to either biodegradable polymer sirolimus-eluting stents or durable polymer everolimus-eluting stents. Central randomisation was done based on a computer-generated allocation sequence with variable block sizes of 2, 4, and 6, which was stratified by centre, diabetes status, and presence or absence of multivessel coronary artery disease, and concealed using a secure web-based system. Patients and treating physicians were aware of group allocations, whereas outcome assessors were masked to the allocated stent. The experimental stent (Orsiro; Biotronik; Bülach, Switzerland) consisted of an ultrathin strut cobalt-chromium metallic stent platform releasing sirolimus from a biodegradable polymer. The control stent (Xience Xpedition/Alpine; Abbott Vascular, Abbott Park, IL, USA) consisted of a thin strut cobalt-chromium stent platform that releases everolimus from a durable polymer. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial reinfarction (Q-wave and non-Q-wave), and clinically-indicated target lesion revascularisation, within 12 months of the index procedure. All analyses were done with the individual participant as the unit of analysis and according to the intention-to-treat principle. The trial was registered with ClinicalTrials.gov, number NCT02579031.
FINDINGS: Between April 26, 2016, and March 9, 2018, we randomly assigned 1300 patients (1623 lesions) with acute myocardial infarction to treatment with biodegradable polymer sirolimus-eluting stents (649 patients and 816 lesions) or durable polymer everolimus-eluting stents (651 patients and 806 lesions). At 12 months, follow-up data were available for 614 (95%) patients treated with biodegradable polymer sirolimus-eluting stents and 626 (96%) patients treated with durable polymer everolimus-eluting stents. The primary composite endpoint of target lesion failure occurred in 25 (4%) of 649 patients treated with biodegradable polymer sirolimus-eluting stents and 36 (6%) of 651 patients treated with durable polymer everolimus-eluting stents (difference -1·6 percentage points; rate ratio 0·59, 95% Bayesian credibility interval 0·37-0·94; posterior probability of superiority 0·986). Cardiac death, target vessel myocardial reinfarction, clinically-indicated target lesion revascularisation, and definite stent thrombosis were similar between the two treatment groups in the 12 months of follow-up.
INTERPRETATION: In patients with acute STEMI undergoing primary PCI, biodegradable polymer sirolimus-eluting stents were superior to durable polymer everolimus-eluting stents with respect to target lesion failure at 1 year. This difference was driven by reduced ischaemia-driven target lesion revascularisation in patients treated with biodegradable polymer sirolimus-eluting stents compared with durable polymer everolimus-eluting stents.
参考来源
- Iglesias JF, Muller O, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019. PMID: 31488372. doi:10.1016/S0140-6736(19)31877-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。